DelveInsight’s “Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Diabetic Retinopathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Diabetic Retinopathy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Diabetic Retinopathy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Diabetic Retinopathy: An Overview
Diabetic retinopathy (DR) is a microvascular disorder occurring due to the long-term effects of diabetes, leading to vision-threatening damage to the retina, eventually leading to blindness. Diabetic retinopathy affects people with diagnosed or undiagnosed diabetes mellitus. The propensity of developing diabetic retinopathy is directly proportional to the age of the patient and the duration of diabetes, as well as with poor glycemic control and fluctuation in blood pressure level.
In the early stages, most people experience no signs of DR. Symptoms of DR include blurred or distorted vision, new color blindness, night blindness, eye floaters, or streaks in vision, and trouble reading or seeing faraway objects. DR develops in stages over time, including, background retinopathy, pre-proliferative retinopathy, and proliferative retinopathy.
Treatment options for curing Diabetes Retinopathy include anti-VEGF medications (Lucentis, Eylea, and others), Laser treatment, and Eye Surgery. People with uncontrolled diabetes have a higher risk of developing eye problems that look similar to diabetic retinopathy like, Macular edema. With timely treatment, vision loss is prevented and delay diabetic retinopathy progression. After diabetic retinopathy treatment, there are proper chances of a positive outcome if diabetes and blood sugar are well-controlled.
Diabetic Retinopathy Market Key Facts
-
The total 7MM prevalent cases of Diabetic retinopathy were 12,585,769 in 2021.
-
According to a meta-analysis on the Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045 by Teo et al., 2021, there are approximately 93 million patients suffering from DRs, 17 million patients with proliferative DRs, and 21 million patients with diabetic macular edema, worldwide. These data highlight the significant global public health burden of DR.
-
According to secondary research by analysts at DelveInsight, it is estimated that the prevalence of DR is slightly higher in males as compared to females.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Diabetic Retinopathy pipeline therapies. It also thoroughly assesses the Diabetic Retinopathy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Diabetic Retinopathy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Diabetic Retinopathy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Diabetic Retinopathy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Diabetic Retinopathy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Diabetic Retinopathy Epidemiology, Segmented as –
-
Total Prevalent cases of Diabetic retinopathy
-
Gender-specific cases of Diabetic retinopathy
-
Severity-specific cases of Diabetic Retinopathy
-
Age-specific cases of Diabetic Retinopathy
Diabetic Retinopathy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Diabetic Retinopathy market or expected to be launched during the study period. The analysis covers the Diabetic Retinopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Diabetic Retinopathy drugs based on their sale and market share.
The report also covers the Diabetic Retinopathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Diabetic Retinopathy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Diabetic Retinopathy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/diabetic-retinopathy-market
Diabetic Retinopathy Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Diabetic Retinopathy. Currently, Kodiak Sciences is leading the therapeutics market with its Diabetic Retinopathy drug candidates in the most advanced stage of clinical development.
Diabetic Retinopathy Companies Actively Working in the Therapeutics Market Include
-
Kodiak Sciences
-
Novartis
-
Regenxbio Inc.
-
OcuTerra Therapeutics
-
Ocular Therapeutix
-
Bayer
-
RemeGen
-
Roche
-
Ocuphire Pharma
-
Adverum Biotechnologies
-
Boehringer Ingelheim
And Many Others
Emerging and Marketed Diabetic Retinopathy Therapies Covered in the Report Include:
-
KSI-301: Kodiak Sciences
-
Brolucizumab: Novartis
-
RGX 314: Regenxbio Inc.
-
OTT-166: OcuTerra Therapeutics
-
OTX-TKI: Ocular Therapeutix
-
OPT-302: Opthea Limited
-
Runcaciguat (BAY 1101042): Bayer
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/diabetic-retinopathy-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Diabetic Retinopathy Competitive Intelligence Analysis
4. Diabetic Retinopathy Market Overview at a Glance
5. Diabetic Retinopathy Disease Background and Overview
6. Diabetic Retinopathy Patient Journey
7. Diabetic Retinopathy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Diabetic Retinopathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Diabetic Retinopathy Unmet Needs
10. Key Endpoints of Diabetic Retinopathy Treatment
11. Diabetic Retinopathy Marketed Therapies
12. Diabetic Retinopathy Emerging Drugs and Latest Therapeutic Advances
13. Diabetic Retinopathy Seven Major Market Analysis
14. Attribute Analysis
15. Diabetic Retinopathy Market Outlook (In US, EU5, and Japan)
16. Diabetic Retinopathy Companies Active in the Market
17. Diabetic Retinopathy Access and Reimbursement Overview
18. KOL Views on the Diabetic Retinopathy Market
19. Diabetic Retinopathy Market Drivers
20. Diabetic Retinopathy Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/diabetic-retinopathy-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Peripheral Neuritis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Peripheral Neuritis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Peripheral Neuritis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/